Evolus (NASDAQ:EOLS) Reaches New 12-Month Low – Time to Sell?

Evolus, Inc. (NASDAQ:EOLS)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $8.81 and last traded at $8.83, with a volume of 406801 shares changing hands. The stock had previously closed at $9.36.

Analysts Set New Price Targets

Several brokerages recently commented on EOLS. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday. Barclays increased their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Thursday.

Evolus Price Performance

The business has a fifty day moving average of $12.98 and a 200 day moving average of $13.37. The firm has a market cap of $606.62 million, a P/E ratio of -10.48 and a beta of 0.97. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Insider Transactions at Evolus

In other news, insider David Moatazedi sold 6,251 shares of the firm’s stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares in the company, valued at approximately $6,306,875.60. This trade represents a 1.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Karah Herdman Parschauer sold 12,888 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the transaction, the director now owns 32,183 shares in the company, valued at approximately $418,057.17. This trade represents a 28.59 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 60,575 shares of company stock worth $794,369. 6.10% of the stock is owned by company insiders.

Institutional Trading of Evolus

Institutional investors have recently added to or reduced their stakes in the company. KBC Group NV bought a new position in Evolus during the 4th quarter worth $49,000. IFP Advisors Inc grew its stake in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Evolus during the fourth quarter worth about $106,000. Rafferty Asset Management LLC acquired a new stake in Evolus in the 4th quarter worth about $115,000. Finally, Quantbot Technologies LP bought a new stake in Evolus in the 4th quarter valued at about $118,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.